Philip Turpin

Profil Philip Turpin

Philip advises private equity sponsors, management teams, portfolio companies and strategic investors, as well as public companies, on a range of corporate matters, including mergers and acquisitions, leveraged buyouts, joint ventures, carve-out transactions, reorganizations and general corporate matters.

Philip's experience encompases a range of industries that include energy, infrastructure, industrials, financial services, fintech and consumer products.

Mandate

• Aera Energy, LLC (Aera) and its owners, IKAV and CPP Investments, in the merger of Aera with California Resources Corporation
• The Special Committee of the Board of Directors of Sculptor Capital Management in its sale to Rithm Capital
• Odyssey Investment Partners in its acquisition of Magna Legal Services from CIVC Partners, LP
• The parent company of EagleClaw Midstream, a Blackstone and I Squared Capital portfolio company, in a merger with Altus Midstream, forming the largest integrated midstream company in the Delaware Basin with an estimated enterprise value of $9 billion at the time 
• Epiris on its acquisition of LoneStar Group, a leading global manufacturer and supplier of precision-engineered components and pipeline packages
• Epiris on the demerger of Fastmarkets from Delinian
• Roan Resources in its $1 billion sale to Citizen Energy Operating, LLC
• Oasis Petroleum in the simplication of Oasis Midstream Partners and drop-down of Bobcat Devco and Beartooth Devco
• LRS, an independent waste diversion, recycling and portable services provider, and Goldman Sachs, as lead investor in LRS, in the sale of LRS to an affiliate of Macquarie Infrastructure Partners
• Luxe Energy LLC (Luxe) in connection with a strategic transaction under which Colgate Energy Partners III, LLC acquired a majority of the assets owned by Luxe
• Joe Naggar and Republic Digital on the acquisition of Golden Tree Asset Management's digital asset division by Republic Digital 
• Open Co (formerly Geru) in its acquisition of BizCapital
• Homology Medicines, Inc. in its merger with Q32 Bio Inc.

* This deal list includes work that Philip completed while at a prior firm.